Production (Stage)
Tiziana Life Sciences Ltd
TLSA
$1.58
$0.2115.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.03% | -4.51% | -15.91% | 57.25% | 505.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.18% | -14.03% | -15.81% | 1.30% | 23.30% |
| Operating Income | 12.18% | 14.03% | 15.81% | -1.30% | -23.30% |
| Income Before Tax | 2.88% | 9.23% | 14.85% | 3.01% | -11.98% |
| Income Tax Expenses | -1,187.53% | -1,828.29% | -- | -- | -- |
| Earnings from Continuing Operations | 32.94% | 31.19% | 29.60% | 9.97% | -14.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.94% | 31.19% | 29.60% | 9.97% | -14.90% |
| EBIT | 12.18% | 14.03% | 15.81% | -1.30% | -23.30% |
| EBITDA | 12.21% | 14.07% | 15.84% | -1.28% | -23.30% |
| EPS Basic | 35.92% | 32.24% | 28.86% | 9.25% | -15.37% |
| Normalized Basic EPS | 14.98% | 18.46% | 21.63% | 4.97% | -16.29% |
| EPS Diluted | 35.92% | 32.24% | 28.86% | 9.25% | -15.37% |
| Normalized Diluted EPS | 14.98% | 18.46% | 21.63% | 4.97% | -16.29% |
| Average Basic Shares Outstanding | 4.10% | 1.64% | -0.78% | 0.06% | 0.93% |
| Average Diluted Shares Outstanding | 4.10% | 1.64% | -0.78% | 0.06% | 0.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |